Treatment of Multicentric Castleman Disease

Multicentric Castleman disease (MCD) is usually much harder to treat than localized CD. There is no standard therapy for MCD, and no single treatment works for all patients. Several types of treatment have been shown to help some patients. But because MCD is rare, it has been hard for doctors to compare different treatments against each other in clinical trials.

Surgery is used to biopsy an affected lymph node to make the diagnosis, but MCD is too widespread to remove it all with surgery or treat it effectively with radiation. Still, some people are helped by these treatments. For example, surgery is sometimes used to remove an enlarged spleen that is causing symptoms, or radiation can be used to shrink tumors in a specific area that are causing problems.

More often, doctors use treatments that can reach all parts of the body, such as corticosteroids, chemotherapy, or immunotherapy, when treating MCD. Doctors usually try one or a combination of these treatments to try to put the disease into remission. Anti-viral drugs including anti-HIV treatment may also help.

In some patients the disease shrinks or even goes away completely with treatment, at least for a time. In others, the benefit does not last long and symptoms come back once treatment is stopped. Some patients may not be helped by these drugs at all.

In people whose MCD is no longer responding to other treatments, some doctors might recommend high-dose chemotherapy followed by a stem cell transplant. There are a few reported cases of this being successful. This is a complex, serious, and often expensive treatment, so it’s important to understand what it might entail if you are considering this option. For more on this treatment, see Stem Cell Transplant for Cancer.

The long-term outlook (prognosis) for people with MCD is often not as good as for people with localized CD. Treatment can often help for a time, but the disease tends to come back within a couple of years. A major concern is that people with MCD are at risk of dying from other causes, like serious infections or progression of the MCD to a fast-growing form of lymphoma that is hard to treat. (For more information about lymphoma, see Non-Hodgkin Lymphoma.)

The outlook for MCD tends to be worse if the person also has HIV/AIDS. Even if the HIV infection is under control with drug treatment, the MCD is not likely to go away. The treatment and outlook of MCD can also be complicated by the presence of Kaposi sarcoma and other AIDS-related conditions. These conditions may be less of a problem if the patient is on anti-HIV treatment.

Because MCD can be hard to treat, taking part in a clinical trial of newer treatments can be a good option for some people. (See What’s New in Research of Castleman Disease? for a description of some newer treatments.)

The American Cancer Society medical and editorial content team
Our team is made up of doctors and master's-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: Novel insights into biology, pathogenesis, and therapy. Blood. 2014;123(19):2924-2933.

Fajgenbaum DC, Kurzrock R. Siltuximab: A targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy. 2016;8(1):17-26.

Fajgenbaum DC, Uldrick TS, Bagg A, et al.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657. 

Gross TG. Immunodeficiency and cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman’s disease: A systematic literature review. Lancet Haematol 2016;3(4):e163-165.  

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. Cancer Sci. 2017;9 [Epub ahead of print].

Munshi NC, Jaggannath S. Plasma cell neoplasms. In: Hematology: Basic Principles and Practice, 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 1381-1418.

National Cancer Institute. Physician Data Query (PDQ). AIDS-related lymphoma treatment. 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq  on January 11, 2018.

National Cancer Institute. Castleman disease. Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018. 

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf  on January 11, 2018 .

National Organization for Rare Disorders. Castleman disease. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20:775–779.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017. 

Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. HIV-associated malignancies. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015:1780-1792.

Last Medical Review: January 12, 2017 Last Revised: February 5, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.